MRKMerck Sharp & Dohme LLCRunning, no new patients
Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054)
Melanoma
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 1,019 (final count)
- Started
- Jul 16, 2015
- Main results expected
- Jan 8, 2018
- Fully finished
- Nov 1, 2026
- Results posted
- Jan 4, 2019
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among All Participants
Measured over: 6 months
Part 1: Percentage of Participants With Recurrence-Free Survival (RFS) At 6 Months Among Participants With PD-L1-positive Tumor Expression
Measured over: 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02362594 · record last updated 2026-03-05 · checked 2026-11-09 15:47 UTC